(The following press release from Merck KGAA was received by e-mail. It  was not confirmed by the sender.)  News Release  Your Contact Andrea Marquart +49 6151 72-6517  Merck Serono Enters into Research Agreement with Pfizer and Broad Institute  • Agreement aims to identify biomarkers relevant to future therapies in the   area of Systemic Lupus Erythematosus and Lupus Nephritis  Darmstadt, Germany, April 1, 2014 – Merck Serono, the biopharmaceutical division of Merck, announced today that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The research project will be jointly funded by Merck Serono and Pfizer.  The complete Merck News Release can be downloaded at the following link:$File/Final_MerckSeron o_BroadPfizer_PressRelease_2014Apr1st_EN.pdf  News Releases from Merck KGaA, Darmstadt, Germany, are available at this address: or for residents in the USA and Canada at  In case you are a resident of the USA or Canada please go to to register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email.  You may change your subscription at any time by following either one of the following links: or And please feel free to unsubscribe this service with either or Thank you very much!  Merck KGaA Group Communications External Communications Frankfurter Str. 250 64293 Darmstadt Germany E-Mail: Mandatory Information can be found at Hotline: +49 6151 72-5000  This message and any attachment are confidential and may be privileged or otherwise protected from disclosure. If you are not the intended recipient, you must not copy this message or attachment or disclose the contents to any other person. If you have received this transmission in error, please notify the sender immediately and delete the message and any attachment from your system. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not accept liability for any omissions or errors in this message which may arise as a result of E-Mail-transmission or for damages resulting from any unauthorized changes of the content of this message and any attachment thereto. Merck KGaA, Darmstadt, Germany and any of its subsidiaries do not guarantee that this message is free of viruses and does not accept liability for any damages caused by any virus transmitted therewith.  Click to access the German, French, Spanish and Portuguese versions of this disclaimer.    
Press spacebar to pause and continue. Press esc to stop.